KR20220126787A - Hiv 및 aids의 치료 및 예방 방법 - Google Patents

Hiv 및 aids의 치료 및 예방 방법 Download PDF

Info

Publication number
KR20220126787A
KR20220126787A KR1020227029968A KR20227029968A KR20220126787A KR 20220126787 A KR20220126787 A KR 20220126787A KR 1020227029968 A KR1020227029968 A KR 1020227029968A KR 20227029968 A KR20227029968 A KR 20227029968A KR 20220126787 A KR20220126787 A KR 20220126787A
Authority
KR
South Korea
Prior art keywords
hiv
administration
once
efda
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227029968A
Other languages
English (en)
Korean (ko)
Inventor
다리아 하주다
마이클 디. 밀러
제이 에이. 그로블러
데보라 앤 니콜-그리피스
Original Assignee
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Priority to KR1020257028942A priority Critical patent/KR20250136420A/ko
Publication of KR20220126787A publication Critical patent/KR20220126787A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
KR1020227029968A 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법 Ceased KR20220126787A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257028942A KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US62/294,576 2016-02-12
US201662297657P 2016-02-19 2016-02-19
US62/297,657 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids
KR1020217012504A KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217012504A Division KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257028942A Division KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Publications (1)

Publication Number Publication Date
KR20220126787A true KR20220126787A (ko) 2022-09-16

Family

ID=58057333

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227029968A Ceased KR20220126787A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020257028942A Pending KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020217012504A Ceased KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020187025948A Active KR102317570B1 (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257028942A Pending KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020217012504A Ceased KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020187025948A Active KR102317570B1 (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Country Status (37)

Country Link
US (4) US10537589B2 (cg-RX-API-DMAC7.html)
EP (1) EP3413897B1 (cg-RX-API-DMAC7.html)
JP (4) JP6810972B2 (cg-RX-API-DMAC7.html)
KR (4) KR20220126787A (cg-RX-API-DMAC7.html)
CN (2) CN108697727A (cg-RX-API-DMAC7.html)
AU (3) AU2017217656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018016349A2 (cg-RX-API-DMAC7.html)
CA (1) CA3013473C (cg-RX-API-DMAC7.html)
CL (1) CL2018002150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3413897T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000183A (cg-RX-API-DMAC7.html)
EA (1) EA201891814A1 (cg-RX-API-DMAC7.html)
ES (1) ES2953535T3 (cg-RX-API-DMAC7.html)
FI (1) FI3413897T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20217231B (cg-RX-API-DMAC7.html)
HR (1) HRP20230935T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063532T2 (cg-RX-API-DMAC7.html)
IL (1) IL260874B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20170038B1 (cg-RX-API-DMAC7.html)
LT (1) LT3413897T (cg-RX-API-DMAC7.html)
MD (1) MD3413897T2 (cg-RX-API-DMAC7.html)
MX (3) MX390604B (cg-RX-API-DMAC7.html)
MY (1) MY197090A (cg-RX-API-DMAC7.html)
NI (1) NI201800083A (cg-RX-API-DMAC7.html)
NZ (1) NZ745065A (cg-RX-API-DMAC7.html)
PH (1) PH12018501712A1 (cg-RX-API-DMAC7.html)
PL (1) PL3413897T3 (cg-RX-API-DMAC7.html)
PT (1) PT3413897T (cg-RX-API-DMAC7.html)
RS (1) RS64448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201806783WA (cg-RX-API-DMAC7.html)
SI (1) SI3413897T1 (cg-RX-API-DMAC7.html)
SV (1) SV2018005733A (cg-RX-API-DMAC7.html)
TN (1) TN2018000267A1 (cg-RX-API-DMAC7.html)
TW (3) TWI822652B (cg-RX-API-DMAC7.html)
UA (1) UA126375C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017139519A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805073B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
EP3897660A4 (en) * 2018-12-20 2022-09-07 Merck Sharp & Dohme Corp. NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
EP4358968A4 (en) * 2021-06-22 2025-05-07 Rome Therapeutics, Inc. 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
KR20110079783A (ko) 2003-02-19 2011-07-07 예일 유니버시티 항-바이러스 뉴클레오시드 유사체 및 바이러스 감염, 특히 에이치아이브이 감염의 치료방법
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
EP3471829A4 (en) * 2016-06-20 2020-01-15 Merck Sharp & Dohme Corp. ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
US20230149296A1 (en) * 2020-05-05 2023-05-18 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
US20250073254A1 (en) 2025-03-06
JP7559175B2 (ja) 2024-10-01
TWI822652B (zh) 2023-11-21
FI3413897T3 (fi) 2023-08-25
RS64448B1 (sr) 2023-09-29
CA3013473A1 (en) 2017-08-17
GEP20207190B (en) 2020-12-10
AU2017217656B2 (en) 2020-01-30
NI201800083A (es) 2018-10-05
JP7021314B2 (ja) 2022-02-16
MY197090A (en) 2023-05-24
JP6810972B2 (ja) 2021-01-13
MX2022002924A (es) 2022-12-15
KR20210049201A (ko) 2021-05-04
TW201731514A (zh) 2017-09-16
JP2021001189A (ja) 2021-01-07
GEP20217231B (en) 2021-03-25
WO2017139519A1 (en) 2017-08-17
KR20180108815A (ko) 2018-10-04
JP2022062170A (ja) 2022-04-19
AU2022201686A1 (en) 2022-03-31
TW202417010A (zh) 2024-05-01
TWI911551B (zh) 2026-01-11
DK3413897T3 (da) 2023-09-18
LT3413897T (lt) 2023-08-25
US20220331350A1 (en) 2022-10-20
US20200101098A1 (en) 2020-04-02
JP7559175B6 (ja) 2024-10-22
CA3013473C (en) 2021-10-26
EP3413897B1 (en) 2023-06-14
EA201891814A1 (ru) 2019-01-31
JP2019504857A (ja) 2019-02-21
IL260874B2 (en) 2023-10-01
US20180055867A1 (en) 2018-03-01
MX390604B (es) 2025-03-20
AU2017217656A1 (en) 2018-08-23
AU2020202866A1 (en) 2020-05-21
IL260874A (cg-RX-API-DMAC7.html) 2018-09-20
MD3413897T2 (ro) 2023-11-30
HRP20230935T1 (hr) 2023-11-24
UA126375C2 (uk) 2022-09-28
CN108697727A (zh) 2018-10-23
ES2953535T3 (es) 2023-11-14
MX2022002925A (es) 2023-02-10
US10537589B2 (en) 2020-01-21
CL2018002150A1 (es) 2018-12-14
HUE063532T2 (hu) 2024-01-28
AU2020202866B2 (en) 2022-04-07
KR20250136420A (ko) 2025-09-16
PT3413897T (pt) 2023-08-28
SV2018005733A (es) 2018-12-14
TW202610660A (zh) 2026-03-16
NZ784982A (en) 2025-03-28
TN2018000267A1 (en) 2020-01-16
US11337991B2 (en) 2022-05-24
DOP2018000183A (es) 2018-12-31
GEAP202014873A (en) 2020-07-27
EP3413897A1 (en) 2018-12-19
BR112018016349A2 (pt) 2018-12-26
CN113509480A (zh) 2021-10-19
PL3413897T3 (pl) 2023-10-02
SI3413897T1 (sl) 2023-11-30
US12171776B2 (en) 2024-12-24
SG11201806783WA (en) 2018-09-27
MX2018009763A (es) 2018-11-29
ZA201805073B (en) 2019-05-29
PH12018501712A1 (en) 2019-05-15
HK1257347A1 (en) 2019-10-18
JP2024001206A (ja) 2024-01-09
KR102317570B1 (ko) 2021-10-25
NZ745065A (en) 2023-11-24
IL260874B1 (en) 2023-06-01
AU2022201686B2 (en) 2024-08-08
JOP20170038B1 (ar) 2021-08-17

Similar Documents

Publication Publication Date Title
KR102317570B1 (ko) Hiv 및 aids의 치료 및 예방 방법
HK40054462A (en) Methods for treatment and prophylaxis of hiv and aids
AU2018239257A1 (en) HIV post-exposure prophylaxis
HK1257347B (en) Methods for treatment and prophylaxis of hiv and aids
EA042565B1 (ru) СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа
US20220265689A1 (en) Hiv pre-exposure prophylaxis
EP3823632A1 (en) Hiv drug combination for increasing barrier against resistance

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104